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BCG, only vaccine available to prevent tuberculosis, was established in the early 20th century by 
prolonged passaging of a virulent clinical strain of Mycobacterium bovis. BCG Tokyo-172, originally 
distributed within Japan in 1924, is one of the currently used reference substrains for the vaccine. 
Recently, this substrain was reported to contain two spontaneously arising, heterogeneous 
subpopulations (Types I and II). The proportions of the subpopulations changed over time in 
both distributed seed lots and commercial lots. To maintain the homogeneity of live vaccines, 
such variations and subpopulational mutations in lots should be restrained and monitored. We 
incorporated deep sequencing techniques to validate such heterogeneity in lots of the BCG 
Tokyo-172 substrain without cloning. By bioinformatics analysis, we not only detected the two 
subpopulations but also detected two intrinsic variations within these populations. The intrinsic 
variants could be isolated from respective lots as colonies cultured on plate media, suggesting 
analyses incorporating deep sequencing techniques are powerful, valid tools to detect mutations 
in live bacterial vaccine lots. Our data showed that spontaneous mutations in BCG vaccines could 
be easily monitored by deep sequencing without direct isolation of variants, revealing the complex 
heterogeneity of BCG Tokyo-172 and its daughter lots currently in use.
Mycobacterium bovis bacillus Calmette-Guérin (BCG) was established in 1921 after 13 years and 230 
subcultures of its virulent parental Nocard strain on a glycerinated beef-bile-potato medium1. BCG has 
been the only officially registered live vaccine against tuberculosis (TB) for almost a century, and effective 
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BCG mass vaccination campaigns against TB have been conducted worldwide. Since its development, 
the original strain of BCG, maintained at the Pasteur Institute, has been distributed and used to produce 
substrains2,3. These substrains have been used for vaccination and for culture with appropriate passag-
ing to maintain the strains; this has caused accumulation of genetic difference among the substrains. 
Recent studies have reported the genetic diversity among these substrains4–6; this variation has affected 
the respective substrains phenotypically, modifying the lipid components of the cell wall and affecting 
carbon metabolism and antigenicity, for example5,7–11. Moreover, such genetic diversity has the potential 
to affect the stability of the vaccine during medium- and long-term storage. Recently, the World Health 
Organization (WHO) declared that BCG vaccine substrains should be evaluated for appropriate approval 
and application worldwide10,12.
In addition to difference among substrains, variations within each substrain have arisen by sponta-
neous mutations. A well-studied example is BCG Tokyo (BCG Japan), one of the ancestral substrains, 
which was initially transferred from the Pasteur Institute to Japan in 192413. A freeze-dried seed lot, 
Tokyo-172, was found to contain at least two subpopulations that exhibited different colony morphol-
ogies (Types I and II)14,15. Consecutive seed lots of the substrain were propagated and subcultured to 
mass-produce the final bulk stock prior to the improvement of freeze-drying techniques, which may 
have been involved in the generation of mutations and the accumulation of genetic variants within 
the substrain. As a concrete example, the Type I subpopulation of Tokyo-172, which exhibits smooth 
colonies, is genetically characterized by a unique 22-bp deletion, which has been named RD1615, in the 
JTY3475 gene (an ortholog of Rv3405 of Mycobacterium tuberculosis H37Rv) compared with reference 
sequences of clinical strains, such as M. bovis AF2122/97 and M. tuberculosis H37Rv. In contrast to the 
thorough description of the Type I genomic sequence16, the Type II subpopulation, which can be dis-
tinguished from Type I organisms by its rough-shaped colonies, has remained genetically uncharacter-
ized. Recently, a frameshift missense error of ppsA, found exclusively in the Type II subpopulation, was 
reported to affect the cell wall components17. Therefore, a complicated heterogeneous mixture of the two 
subpopulations exists in the BCG Tokyo-172 substrain. Such natural diversification, e.g., heterogeneity 
on duplication of the DU2 region in the BCG Danish substrain5, commonly occurs in BCG substrains 
and can be exacerbated by continuous passage without appropriate cloning due to natural mutations and 
selective pressure in culture media.
Deep sequencing using next-generation sequencing (NGS) technologies has been developing rapidly 
and has enabled researchers to analyse variations in nucleotides in genetically distinct populations of 
various species18–21. Deep sequencing may unveil not only a priori differences between substrains but 
also de novo heterogeneity within a substrain without requiring the cloning of variants. As an example, 
the intra-lot variation in the oral poliovirus vaccine has already been successfully evaluated by NGS 
techniques22,23, providing important information for maintenance of the homogeneity of live vaccines. 
Such an approach allows us to observe, characterize, and examine undesirable heterogeneity in microbial 
resources caused by spontaneous genetic mutations.
In this study, we used NGS techniques to describe the heterogeneity in separate lots of the BCG 
Tokyo-172 substrain, including two commercial lots from overseas distributees. This approach can be 
used to detect genetic variations in live resources and contributes to the management of heterogeneity 
in cell seed lot systems.
Results
Genomic characterization of two subpopulations in the BCG Tokyo-172 substrain. In a prior 
investigation of the heterogeneity of seed and commercial lots, the genomic variation between Type I 
and II subpopulations of the BCG Tokyo-172 substrain was verified by mapping analysis using NGS 
short reads. In addition to an already-known difference (a frameshift mutation in the ppsA gene)17, six 
nucleotide substitutions were newly identified (Table 1). In comparison with outgroup substrains, these 
nucleotide changes were assigned to both Type I and II subpopulations, indicating that genetic diver-
sification occurred not in one of the two subpopulations unilaterally, but in both subpopulations after 
their divergence.
Subpopulations in seed/commercial lots of BCG Tokyo-172. Next, to assess the heterogeneity 
in lots of BCG Tokyo-172, five domestic seed and commercial lots and two foreign commercial lots 
were sampled and characterized genetically (Fig.  1). The domestic lots included two sequential seeds, 
Tokyo-172 and its daughter seed lot, Tokyo-172-1. Three remaining lots (K-1242-F, K1478L, and KH130) 
were commercially available; these had been propagated and freeze-dried from Tokyo-172 or Tokyo-
172-1. The two foreign lots, BG039304 and 1A-825-43, were commercial lots received from Taiwan and 
Thailand, respectively. BCG substrains in current use in both areas had been obtained from Japan after 
the establishment of Tokyo-1722,24,25 and were then produced independently as applied vaccines in the 
respective countries.
First, from each lot, the two subpopulations, Types I and II, were quantified according to the RD16 
genomic deletion. Two seed lots, Tokyo-172 and Tokyo-172-1, contained 36.8% ± 1.6% and 14.9% ± 0.6% 
of the Type II subpopulation, respectively (Fig.  2). The Type II subpopulation was predominated in 
domestic commercial lots (K-1242-F: 1.7% ± 0.1%, K1478L: 12.8% ± 0.9%, and KH130: 5.8% ± 0.2%). 
Overall, the proportion of the Type II subpopulation decreased with increasing passages. These results 
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correspond with those of a previous report14. A commercial lot from Taiwan (BG039304) contained 
40.4% ± 1.9% of the Type II subpopulation, showing genetic similarity to the original seed lot, Tokyo-
172. In contrast, the RD16 deletion genotype was not detected by polymerase chain reaction (PCR) in a 
commercial lot from Thailand 1A-825-43.
Deep sequencing analysis. Deep sequencing based on an Illumina platform provides massive 
sequence data at each nucleotide position in a genome; this analysis can capture genetic fluctuations 
quantitatively in a population of bacilli. With this perspective, the collected BCG lots were subjected to 
deep sequencing to evaluate the potential for use of this technique to measure the proportion of subpop-
ulations and to detect spontaneous inherent variations.
To monitor genomic regions as broadly as possible, the read data from each BCG lot were mapped 
to reference sequences (BCG Tokyo-172 substrain Type I). The average depths mapped to the references 
ranged from 299.07 to 484.65 (average: 400.05, by a mapping tool Bowtie 2; Supplementary Table 1). 
With the read quantity, about 90% of nucleotide sequences of the reference genomes were mapped by 
the reads with a read depth of more than 200 (Fig. 3), which guaranteed subsequent detection of heter-
ogeneity in a broad range with high accuracy. Indeed, the seven polymorphisms found between the two 
subpopulations (Table 1) were successfully detected, and the proportions of Type I and II subpopulations 
in each lot were determined for all lots, except for K-1242-F, the commercial lot having the lowest pro-
portion of the Type II subpopulation in our samples (Table 2).
We incorporated three bioinformatics tools to detect heterogeneity of BCG lots. LoFreq called the 
variation most consistently, although this tool cannot detect indel variations, such as the insertion var-
iant at 3,192,638 (ppsA). SNVer and Breseq can detect both substitution and indel variations in their 
separate, respective files. However, the proportion of variants with this insertion, as determined by 
SNVer, deviated from that of the other variant calls inconsistently. In contrast, the insertion could be 
detected by Breseq, consistent with other substitutions. Breseq could also detect the 22-bp deletion of 
Position*
BCG Tokyo Early distributed strains
M. bovis AF2122/97 Gene AnnotationI II BCG Russia BCG Moreau
253,186§ A G A A A pckA Y390C
644,562§ T C T T T JTY_0567 I144T
765,342§ C T T T T rpoC A68V
2,717,585§ C T T T T intergenic† –
3,192,638 . A . . . ppsA frameshift
3,606,131§ G A A A A JTY_3278 T54I
4,087,391§ C T T T T JTY_3735 A184V
Table 1.  Single nucleotide polymorphisms between subpopulations of M. bovis BCG Tokyo. 
*Correspondent to nucleotide positions of genome sequence of M. bovis BCG Tokyo Type I (Accesion No. 
NC012207). †Left gene: clpX, right gene: mmuM. §SNVs identified in this study.
Figure 1. A historical record of recent lots of BCG Tokyo analysed in this study. Seven rectangle boxes 
correspond to BCG lots that were subjected to deep sequencing. Arrows indicate culturing processes to 
establish or produce descendant lots from each seed lot.
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RD16, although its sensitivity for detection of substitutive variants seemed lower than those of LoFreq 
and SNVer (Table  2). For example, Breseq failed to consistently detect variations at positions 644,562 
(JTY_0567) and 3,606,131 (JTY_3278), although these variations were detected by LoFreq and SNVer.
To apply this method to other substrains, a reference sequence must be applied by integration of sev-
eral genomes to account for the deleted regions of each substrain. For this purpose, we supplemented the 
entire sequence of BCG Tokyo-172 with other genome sequences (BCG Moreau RDJ, another candidate 
of the reference substrain of BCG, and M. bovis AL2122/97; Supplementary GenBank File 1). When it 
was used to replace the original sequence, the variation could be detected exactly as described in Table 2.
Figure 2. Heterogeneity of Type I and II subpopulations in each BCG lot was monitored based on the 
RD16 region. (A) Agarose gel electrophoresis of PCR products of the RD16 region. (B) Ratios of intact/
deleted RD16 in each lot were calculated from the copy numbers derived from quantitative real-time PCR. 
The Y-axis shows the percentage of respective lots that were of the Type II subpopulation. The error bars 
indicate the propagated standard deviation (± 2σ ) of respective ratios.
Figure 3. Percentage of covered nucleotides of the reference genome sequence (NC_012207, 
4,171,711 bp) mapped with short reads from seven seed/commercial lots of Tokyo-172 by Bowtie2 
(incorporated in Breseq v0.24rc6). The X-axis shows the depth of reads covering the reference genome, and 
the Y-axis shows the % of the reference sequence mapped with the depth. Short reads were obtained twice 
(A,B) from the same lots and used for subsequent analysis.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:17827 | DOI: 10.1038/srep17827
Position* (gene)
BCG Tokyo Frequency of nucleotide variants (=Type II) estimated by each package†
1A-825-43I II Tokyo-172 Tokyo-172-1 K-1242-F KH130 K1478L BG039304
253,186 (pckA) A G Breseq 35.8/35.7 16.5/17.5 n.d./n.d. 2.4/4.4 13.0/9.0 40.5/39.1 100/100
LoFreq 35.1/35.6 16/17.9 n.d./n.d. 2.4/4.6 12.4/8.8 40.0/39.1 100/100
SNVer 36.8/36.4 17.3/17.9 n.d./n.d. n.d./4.6 13.5/9.0 41.2/40.0 100/100
644,562 (JTY_0567) T C Breseq 35.6/n.d§ 19.0/n.d. n.d./n.d. 2.6/3.4 9.4/9.6 40.0/n.d. 100/100
LoFreq 32.8/34.8 17.3/17.0 n.d./n.d. 2.4/3.3 9.3/9.3 38.3/47.2 99.8/99.6
SNVer 35.0/36.1 18.3/18.0 n.d./n.d. 2.5/3.7 10.1/9.3 40.9/48.5 99.8/99.6
765,342 (rpoC) C T Breseq 42.2/33.3 16.7/18.8 n.d./n.d. 2.7/n.d. 10.8/11.7 40.4/40.9 100/100
LoFreq 40.5/34.4 15.2/19.1 n.d./n.d. 2.6/3.5 10.8/11.3 39.0/41.2 99.7/99.6
SNVer 43.8/35.0 18.0/19.1 n.d./n.d. n.d./n.d. 11.9/11.6 41.8/42.0 99.7/99.6
2,717,585 (intergenic†) C T Breseq 40.0/38.5 18.0/20.9 1.4/n.d. 7.2/6.8 10.9/12.4 43.2/47.7 100/100
LoFreq 39.3/38.5 16.6/21.4 n.d./n.d. 6.8/6.6 10.4/12.4 41.9/47.7 100/99.8
SNVer 41.9/39.8 19.0/22.5 n.d./n.d. 7.0/6.8 11.3/12.8 44.7/48.5 100/99.8
3,192,638 (ppsA) . A Breseq 34.3/35.2 17.1/19.8 n.d./n.d. 4.3/2.9 10.2/9.8 38.1/45.3 100/n.d.
LoFreq – – – – – – –
SNVer 23.7/47.2 n.d./15.3 n.d./n.d. n.d./n.d. n.d./8.6 26.4/29.3 46.6/47.2
3,606,131 (JTY_3278) G A Breseq n.d./40.6 n.d./19.6 n.d./n.d. 4.7/5.0 n.d./10.2 n.d./n.d. 100/100
LoFreq 43.2/39.9 22.5/19.2 3.1/n.d. 4.7/4.6 12.1/10.1 37.3/41.6 100/100
SNVer 44.9/41.4 23.7/20.1 n.d./n.d. 5.1/n.d. 13.1/10.4 39.1/43.3 100/100
4,087,391 (JTY_3735) C T Breseq 38.8/39.1 17.1/18.3 n.d./n.d. 3.4/3.3 9.0/13.8 43.0/42.7 100/100
LoFreq 38.8/40.2 17.0/18.8 n.d./n.d. 3.3/3.7 9.0/14.2 42.3/43.8 100/99.7
SNVer 39.7/40.9 17.5/19.5 n.d./n.d. 3.5/3.7 9.9/14.7 43.9/44.6 100/99.7
Table 2.  Detection of heterogeneity of type I/II variants in seed and commercial lots of M. bovis 
BCG Tokyo. *Correspondent to nucleotide positions of genome sequence of M. bovis BCG Tokyo Type 
I (Accesion No. NC012207). †Two frequency scores estimated from two read data of each BCG lot are 
tandemly indicated respectively. §n.d. not detected. ‡Left gene: clpX, right gene: mmuM.
Monitoring intrinsic heterogeneity in BCG lots. In addition to the complexity of Type I and II 
substrains, spontaneous heterogeneity in the BCG lots was also determined by variant calls. From mon-
itoring of NGS data, we estimated that only two lots may have contained minor heterogeneity (Table 3) 
in over 5% of the total population.
One of the two intrinsic variants (Tokyo-172) was detected in the most ancestral seed lot in this 
study (Table 3). The variant was not found in descendant lots, indicating that the variant had not been 
positively selected in subsequent passages. The other heterogeneous lot was 1A-825-43; this was a com-
mercial lot, and the variant would not be inherited in subsequent propagation, although the variant may 
be contaminated from its seed lot. To verify this bioinformatic estimation, we cultured the BCG lots 
on agar plates and tried to isolate variant clones directly from the colonies grown. As a result, mutated 
colonies were indeed isolated from the two BCG lots (Table 3).
Discussion
BCG Tokyo-172 is one of four candidate WHO reference strains26,27. Two types of colonies showing 
different morphologies were found when Tokyo-172 was cultured on agar plates15; and these variants 
were thought to be caused by complex heterogeneity16,17. In this study, to monitor hidden heterogeneity 
in lot stocks of BCG Tokyo-172, deep sequencing analysis was performed. We successfully identified and 
characterized two subpopulations (Types I and II) of this strain, providing insights into the acquisition 
of heterogeneity in vaccine strains.
BCG has been used in vaccine production for almost a century. This long period of maintenance and 
worldwide distribution has resulted in wide genetic diversity among substrains5,15. This could also cause 
genetic heterogeneity within respective substrains, such as Type I and II subpopulations in BCG Tokyo-
172. Although there is no evidence showing that heterogeneity affects the efficacy or antigenicity of the 
BCG vaccine directly, this feature should be controlled by certain procedures in order to maintain the 
stability of the vaccine. Monitoring of unpredictable variation across the entire genome was difficult in 
the past; however, with major advancements in deep sequencing analysis based on NGS technologies, 
such monitoring has become possible. Indeed, deep sequencing is now suitable for effective detection 
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of spontaneous variation within a biotic resource and may become the new standard for quality control 
of new lots.
In this study, we examined seven derivative lots of Tokyo-172 to investigate their heterogeneity. The 
substrain BCG Tokyo-172 has been reported to include two subpopulations, identifiable by their colony 
morphology and genetic differences15,17. This readily detectable diversity provides a good indicator to 
evaluate the use of NGS techniques to identify heterogeneity within BCG lots. In our study, seven nucleo-
tide polymorphisms were identified between Type I and II subpopulations and could be representative of 
heterogeneous mutations in each lot. The results showed that deep sequencing analysis could be applies 
as a standard method to test the heterogeneity of BCG vaccines quantitatively.
If we are to assume that there was a historical process of subdivision of the BCG Tokyo-172 substrain, 
it is important that both Type I and II subpopulations possess their own unique polymorphisms. Other 
substrains (BCG Russia and Moreau) that were distributed from the Pasteur Institute during the same 
period as BCG Tokyo do not share the seven polymorphisms of the subpopulations. Thus, these poly-
morphisms may have accumulated separately during passages in Japan. However, it is not clear why such 
heterogeneity has occurred, particularly because the cloning processes of the substrain over this period 
have not been recorded.
The heterogeneity in each lot of BCG Tokyo-172 can be interpreted as a mixture of the major poly-
morphisms between the two subpopulations; in contrast, the number of spontaneous variants was low. 
Respective subpopulations were highly clonal, suggesting that they may have been generated via cloning 
steps just before the establishment of Tokyo-172. After establishment of Tokyo-172, the proportion of 
the Type II subpopulation may have decreased during passaging. The most dramatic decrease was found 
in K-1242-F, a commercial lot propagated directly from Tokyo-172. However, it is not clear why this lot 
had such a lower proportion of the Type II subpopulation than the other lots derived from Tokyo-172-1. 
It is possible that some conditions of lot preparation, such as nutrient components and temperature in 
culture, may affect the proportions of certain subpopulations. Further in vitro experiments are needed to 
check this hypothesis. In contrast to the heterogeneity in domestic lots, the Type I subpopulation could 
not be detected in a commercial lot from Thailand. Therefore, some type of cloning process may have 
been used to purify the Type II subpopulation in this country.
In contrast to the distinct colony morphology of the subpopulations15, it is generally more difficult 
to identify heterogeneity because there are no obvious clues to isolate distinct variants. From this back-
ground, deep sequencing analyses based on NGS techniques can be used to survey unavoidable sponta-
neous variations without colony isolation. This strategy has been already reported antecedently for the 
monitoring of live attenuated poliovirus vaccines21–23. If genome-wide screening of heterogeneity can be 
incorporated into production of the BCG vaccine, it would be possible to assess the genetic uniformity 
of the vaccine, which could provide a more sustainable supply of stable vaccine lots.
Our approach revealed the complex heterogeneity of a substrain of BCG Tokyo-172. It is impor-
tant to establish a corresponding reference genome sequence for other substrains in order to maintain 
high mapping quality. In this study, we constructed an artificial reference genome from three complete 
genome sequences of M. bovis and BCG substrains; however, further studies are require in order to verify 
the usefulness of this reference sequence for other substrains. Currently, the entire genome sequences 
of two of four candidate WHO reference substrains (i.e., BCG Danish 1331 and Russia I) have not been 
completed. Accumulation of such basic data may improve a variety of analytical methods for evaluation 
of various BCG substrains in the future.
Methods
Culture of BCG lots and DNA preparation. Cloned subpopulations (Types I and II) and seed/
commercial lots of BCG Tokyo-172 and were cultured in 40 mL of Middlebrook 7H9 liquid broth with 
gentle shaking at 37 °C. The culture time was restricted to 2 days (about two generations of the substrain) 
to restrain heterogeneity in the culture as much as possible. Genomic DNAs were prepared from cultured 
bacilli according to a previous report28. Briefly, centrifuged bacilli were delipidated using chloroform and 











Proportion of variants in each lot 
estimated in silico (%)† No of 
variant 
coloniesBreseq LoFreq SNVer
Tokyo172 2,655,559 A G subI M1T 11.3/9.60 10.9/9.54 11.6/10.4 2/189
1A-825-43 4,369,503 G A yidC P249L 7.60/4.00 6.69/4.18 7.47/4.55 5/216
Table 3.  Variant calls of the intrinsic heterogeneity in the respective lots. *Correspondent to nucleotide 
positions of genome sequence of M. bovis BCG Tokyo Type I (Accesion No. NC012207). *These variants 
were also called when our artificial reference (Tokyo_suppl.gbk) was used as the reference for analysis. †Two 
frequency scores estimated from two read data of each BCG lot are tandemly indicated respectively.
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phenol/chloroform extraction from the lysates. The quality and quantity of purified genomic DNA were 
evaluated based on the OD260 and agarose electrophoresis.
Determination of nucleotide variations between BCG Tokyo-172 subpopulations. Purified 
DNAs from two substrains were sequenced on an Illumina MiSeq platform to obtain short reads (DRA: 
DRR029468 and DRR029469), and which were mapped to the complete genome sequence of BCG Tokyo-
172 Type I (GenBank: NC_012207) to identify nucleotide variations that were distinct between the two 
subpopulations using CLC Genomics Workbench (Qiagen Science Inc.). To determine genetic differ-
ences between the Type I and II subpopulations, PCR fragments with the respective variant positions 
were verified by conventional Sanger sequencing. Primer sequences are listed in Supplementary Table 2.
Quantification of the Type I subpopulation in BCG lots. The proportion of subpopulations Types 
I and II in respective BCG lots was determined by the ratio of the genome region RD16 deleted genotype, 
a unique genetic feature of the Type I subpopulation, to the intact genotype, corresponding to the Type 
II subpopulation, using specific real-time PCR probes (Supplementary Table 3). The DNA concentration 
of both types was analysed in triplicate in three independent experiments, using a modified protocol of 
a previous report14. Subsequently, the ratios of the subpopulations were calculated, taking into account 
the propagation of errors29.
Deep sequencing. Purified DNAs from BCG lots were subsequently analysed using an Illumina 
Genome Analyzer IIx (GAIIx; Illumina, Inc.). Libraries were constructed using a Paired-End DNA 
Sample Prep Kit (Illumina, Inc.), and each library was assigned to one lane per lot to obtain sufficient 
data quantity to detect minor heterogenic mutations. To avoid variants that arose during library con-
struction as much as possible, libraries were constructed twice independently from the same purified 
DNAs. In this study, 75 bp of both strands were read by GAIIx, but only the forward strands were used 
for analysis owing to the low quality of the reverse strands. The quality score (QV) of the read data was 
checked by FastQC (ver. 0.10.1; Supplementary Figure S1).
Detection of heterogenic variation. To find heterogenic variation in the reads, three bioinformatics 
tools, Breseq (ver. 0.24rc6)30, LoFreq (ver. 0.6.1)31, and SNVer (ver. 0.5.2)32 were used. All three tools are 
based on mapping to a reference genome sequence, finding subpopulational reads possessing nucleotide 
variants among the total mapped reads, and applying the statistical criteria of strand bias, base call 
quality, and mapping quality to remove pseudo-positive heterogeneity. Before analysis, the original read 
data were trimmed by SolexaQA (ver. 2.2)33 to remove low-quality base calls; from this analysis, base 
calls with a quality score (QV) lower than 20 were excluded, and reads shorter than 25 bp were removed. 
As a condition of Breseq, to filter variant calls, base calls with a QV lower than 20 were excluded from 
the calculation. For LoFreq and SNVer calculations, Burrows-Wheeler Alignment (ver 0.7.7)34 was used 
as the mapping tool. BCG Tokyo-172 Type I (RefSeq: NC_012207) was used as the reference genome 
sequence. Mapping results are summarized in Supplementary Table S1.
Construction of a supplemented reference sequence. To supplement unique deletions in the 
genome sequence of BCG Tokyo-172, other entire genome sequences, i.e., those of BCG Moreau RDJ 
(GenBank: AM412059.2) and M. bovis AL2122/97 (RefSeq: NC_002945.3), were used. In brief, the three 
sequences were aligned using mauveAligner (ver 2.4.0)35, and we verified that these sequences could be 
regarded as entirely syntenic. Deleted regions longer than 20 bp in BCG Tokyo-172 were determined by 
MAFFT (ver. 7)36. Finally, the regions were supplemented manually to construct an intentional genomic 
sequence (4,419,199 bp, 47,788 bp larger than the original sequence). This sequence was automatically 
annotated by MiGAP37 and edited using In silico Molecular Cloning (ver. 5.3; In Silico Biology, Inc.) 
and Artemis (ver. 16.0.0)38.
Sequencing of variant positions. Putative intrinsic variations emerging in BCG lots were identified 
from the variation calls described above as variants representing over 5% of the read data, in duplicate, of 
each lot called by more than two of the three tools. Unreliable variants (located in paralogous or highly 
polymorphic genes, transposons, and repetitive unit regions) were excluded to avoid false-positive or 
-negative calls. To verify the filtered variants in the two BCG lots (Tokyo-172 and 1A-825-43), bacilli 
were cultured directly on 7H11 agar plates, and colonies were isolated. After the respective colonies were 
suspended in DNA-free water and heat killed, the supernatants were used as PCR templates to check the 
putative variant nucleotides by sequencing. PCR and sequencing primers are listed in Supplementary 
Table S4.
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